Reduction of linezolid-associated thrombocytopenia by the dose adjustment based on the risk factors such as basal platelet count and body weight

Diagnostic Microbiology and Infectious Disease

Volumn 79, Issue 1, 2014, Pages 93-97

  Niwa, Takashi ^a   Watanabe, Tamayo ^a   Suzuki, Akio ^a   Ohmori, Tomofumi ^a   Tsuchiya, Mayumi ^a   Suzuki, Tomoyuki ^a   Ohta, Hirotoshi ^a   Murakami, Nobuo ^a   Itoh, Yoshinori ^a  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Basal platelet count; Body weight; Dose adjustment; Linezolid; Thrombocytopenia

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GRAM POSITIVE INFECTION; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VERY ELDERLY; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTOR;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BODY WEIGHT; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; PLATELET COUNT; REGRESSION ANALYSIS; RISK FACTORS; THROMBOCYTOPENIA;

EID: 84898473454     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.01.012     Document Type: Article

References (24)

1. Babcock H.M., Fraser V. Clinical experience with linezolid: a case series of 53 patients. Infect Dis Clin Pract 2002, 11:198-204.
2. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003, 36:159-168.
3. Brier M.E., Stalker D.J., Aronoff G.R., Batts D.H., Ryan K.K., O'Grady M., et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003, 47:2775-2780.
4. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
5. Dryden M.S. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 2011, 66(Suppl 4):iv7-iv15.
6. Falagas M.E., Siempos I.I., Vardakas K.Z. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008, 8:53-66.
7. Fung H.B., Kirschenbaum H.L., Ojofeitimi B.O. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 2001, 23:356-391.
8. Gerson S.L., Kaplan S.L., Bruss J.B., Le V., Arellano F.M., Hafkin B., et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002, 46:2723-2726.
9. Grau S., Morales-Molina J.A., Mateu-de Antonio J., Marín-Casino M., Alvarez-Lerma F. Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother 2005, 56:440-441.
10. Hiraki Y., Tsuji Y., Hiraike M., Misumi N., Matsumoto K., Morita K., et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis 2012, 44:60-64.
11. Liew Y.X., Lee W., Loh J.C., Cai Y., Tang S.S., Lim C.L., et al. Impact of an antimicrobial stewardship programme on patient safety in Singapore General Hospital. Int J Antimicrob Agents 2012, 40:55-60.
12. Lin Y.H., Wu V.C., Tsai I.J., Ho Y.L., Hwang J.J., Tsau Y.K., et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006, 28:345-351.
13. Matsumoto K., Takeshita A., Ikawa K., Shigemi A., Yaji K., Shimodozono Y., et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010, 36:179-181.
14. Niwa T., Suzuki A., Sakakibara S., Kasahara S., Yasuda M., Fukao A., et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther 2009, 31:2126-2133.
15. Orrick J.J., Johns T., Janelle J., Ramphal R. Thrombocytopenia secondary to linezolid administration: what is the risk?. Clin Infect Dis 2002, 35:348-349.
16. Pea F., Viale P., Cojutti P., Del Pin B., Zamparini E., Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012, 67:2034-2042.
17. Raad I., Hachem R., Hanna H., Afif C., Escalante C., Kantarjian H., et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004, 53:646-649.
18. Rao N., Hamilton C.W. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007, 59:173-179.
19. Rayner C.R., Forrest A., Meagher A.K., Birmingham M.C., Schentag J.J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003, 42:1411-1423.
20. Sakoulas G., Brown J., Lamp K.C., Friedrich L.V., Lindfield K.C. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther 2009, 31:1936-1945.
21. Sasaki T., Takane H., Ogawa K., Isagawa S., Hirota T., Higuchi S., et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother 2011, 55:1867-1873.
22. Soriano A., Ortega M., García S., Peñarroja G., Bové A., Marcos M., et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 2007, 51:2559-2563.
23. Sotgiu G., Centis R., D'Ambrosio L., Alffenaar J.W., Anger H.A., Caminero J.A., et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012, 40:1430-1442.
24. Tsuji Y., Hiraki Y., Matsumoto K., Mizoguchi A., Kobayashi T., Sadoh S., et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 2011, 17:70-75.